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Background
DNA methylation of retroviral promoter and enhancer
localized in the provirus 5’ long terminal repeat (LTR) is
considered to be a mechanism of transcriptional sup-
pression that allows retroviruses to evade host immune
responses and antiretroviral drugs. However, the role of
DNA methylation in the control of HIV-1 latency has
never been unambiguously demonstrated, in contrast to
the apparent importance of transcriptional interference
and chromatin structure, and has never been studied in
HIV-1-infected patients.
Methods
We analyzed the relation of latent and reactivated HIV-
1 promoters in a model of Jurkat cell lines and in mem-
ory CD4
+ T cells of long-term aviremic patients by
means of bisulfit sequencing and chromatin immuno-
precipitation in cell-sorted populations. To assess the
resistance of latent HIV-1 to reactivation we exposed
the cells to TNF-a, protein kinase C agonists, inhibitors
of HDAC, and inhibitors of DNA methyltransferases.
Results
We show in an in vitro model of reactivable latency and
in a latent reservoir of HIV-1-infected patients that CpG
methylation of the HIV-1 5’ LTR is an additional epige-
netic restriction mechanism, which controls resistance of
latent HIV-1 to reactivation signals and thus determines
the stability of the HIV-1 latency. CpG methylation acts
as a late event during establishment of HIV-1 latency and
is not required for the initial provirus silencing. Indeed,
the latent reservoir of some aviremic patients contained
high proportions of the non-methylated 5’ LTR. In the
latent reservoir of HIV-1-infected individuals without
detectable plasma viremia, we found HIV-1 promoters
and enhancers to be hypermethylated and resistant to
reactivation, as opposed to the hypomethylated 5’ LTR in
viremic patients. However, even dense methylation of the
HIV-1 5’LTR did not confer complete resistance to reac-
tivation of latent HIV-1 with some histone deacetylase
inhibitors, protein kinase C agonists, TNF-a,a n dt h e i r
combinations with 5-aza-2deoxycytidine: The densely
methylated HIV-1 promoter was most efficiently reacti-
vated in virtual absence of T cell activation by suberoyla-
nilide hydroxamic acid.
Discussion
The latency controlled solely by transcriptional interfer-
ence and by chromatin-dependent mechanisms in the
absence of significant promoter DNA methylation tends
to be leaky and easily reactivable. Tight but incomplete
control of HIV-1 latency by CpG methylation might
have important implications for strategies aimed at era-
dicating HIV-1 infection.
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